III
Pharmaceutical glass & vials
Borosilicate vial and cartridge capacity concentrates in three companies; every injectable ramp strains it.
Borosilicate glass is the unglamorous chokepoint behind every injectable. A vial is not a commodity bottle: it is a Type I borosilicate tube, drawn to pharmacopeia spec, converted on high-precision lines, and qualified into a specific drug's filing. Swapping suppliers triggers stability studies and regulatory change control measured in quarters, so incumbency is sticky and capacity is physical, not virtual.
Who owns it
The choke has two layers. Upstream is borosilicate glass tubing, where the world leans on a short list: SCHOTT, Corning, Nippon Electric Glass and Nipro, with a long tail of Chinese makers. Downstream is converting tube into vials, cartridges and syringes, concentrated in SCHOTT Pharma, Gerresheimer and Stevanato. Corning sits oddly: it makes tubing and owns the Velocity low-friction vial coating but has licensed converting to Gerresheimer, SGD Pharma and Nipro rather than scaling its own vial output. So the listed exposure is really SCHOTT Pharma and Stevanato as pure-play converters, Gerresheimer as a converter with a coating license and a battered balance sheet, and Corning as a tubing supplier whose pharma line is a rounding error inside an optical-glass empire.
What breaks it
Demand. GLP-1 injectables are the structural driver: at Stevanato, GLP-1-related products were roughly 19-20% of 2025 revenue and grew more than 50% year over year, pulling its Nexa prefilled syringe and EZ-fill cartridges. SCHOTT Pharma reports robust demand for prefillable glass syringes tied to GLP-1. The squeeze is selective: high-value ready-to-use (RTU, sterile, pre-washed) formats are tight while standard bulk vials are oversupplied — Gerresheimer's pain. The other accelerant is onshoring. BARDA is directly funding US capacity at both SCHOTT Pharma's Lebanon, PA plant (over $60M, largely BARDA-funded, US high-value capacity tripled) and Stevanato's Fishers, Indiana vial lines (~$95M).
What forces the reprice
The mix shift from standard vials to RTU and prefilled formats is the earnings lever, not unit volume. SCHOTT Pharma's high-value solutions ran 57% of sales in Q1 FY2026; Stevanato guides HVS to 47-48% of 2026 revenue. When these lines fill (Fishers turning gross-margin positive, Lebanon ramping), operating leverage shows up. The catalyst tape is FDA shortage-list changes, BARDA/onshoring milestones, and converter quarterly mix disclosure — plus the divergence between SCHOTT/Stevanato executing and Gerresheimer rebuilding credibility after cutting 2025 guidance twice and disclosing an accounting investigation that delayed reporting.
Be honest about size and earliness
This is a real but small and slow-moving chokepoint, and you can over-narrate it. Corning is the trap: its entire Life Sciences segment is roughly $972M of ~$15.6B FY2025 GAAP net sales, and pharma packaging is only a slice of that — Corning trades on optical and AI-glass demand, not vials. SCHOTT Pharma is the cleanest pure play but is a ~€986M FY2025 revenue company guiding only 2-5% constant-currency growth — a steady compounder, not a vertical ramp, and its US lines are listed only as thin OTC ADRs. Stevanato is the largest and most liquid name (NYSE, ~€1.19B 2025 revenue) but is still ~80% non-GLP-1, so the headline theme is a minority of the business. Gerresheimer is cheap for a reason. And note the policy honesty: the BIOSECURE Act did become law in December 2025 as Section 851 of the FY2026 NDAA, but it targets Chinese biotech CDMO equipment and services, not glass packaging — it is a tailwind for US-onshoring narrative, not a direct binding constraint on this chokepoint. Map plants and qualified-supplier positions, not molecules; the edge is watching RTU mix and US line ramps, not GLP-1 prescription headlines.
Who owns the choke
Corning Incorporated
Diversified glass/ceramics maker; Type I borosilicate tubing supplier and developer of the Velocity low-friction vial coating — a joint venture with Gerresheimer, and licensed to SGD Pharma and Nipro for converting. Life Sciences was ~$972M of ~$15.6B FY2025 GAAP net sales; pharmaceutical packaging is a fraction of that.
- Bull
- Corning supplies Type I borosilicate tubing and its Velocity low-friction vial coating, with a Gerresheimer JV and SGD/Nipro licenses positioning it across the concentrated pharma-glass choke.
- Bear
- Life Sciences is only ~$972M of ~$15.6B FY2025 sales and pharma packaging a fraction of that, so glass upside is immaterial to the broader Corning story.
Gerresheimer AG
German glass and plastics packaging/medical-systems maker; one of three major vial/cartridge converters and a Corning Velocity coating licensee. 2025 was rough: organic revenue guided to decline 2-4% after two cuts, an accounting probe delayed financials, and the OTC line traded near \$32 (≈\$1B market cap, down ~48%).
- Bull
- Gerresheimer is one of three major vial and cartridge converters and a Corning Velocity licensee, leveraged to any injectable ramp that strains concentrated glass capacity.
- Bear
- A rough 2025 brought two guidance cuts, an accounting probe delaying financials, and the OTC line down ~48%, leaving a speculative name with damaged credibility.
Nippon Electric Glass Co., Ltd.
Japanese glass conglomerate; manufactures Type I borosilicate glass tubing for pharmaceutical ampoules, vials and syringes meeting US/EU/JP pharmacopeia standards. Pharma tubing is a minor product line within a business dominated by display, glass fiber and electronics materials.
- Bull
- Nippon Electric Glass makes pharmacopeia-grade Type I borosilicate tubing for ampoules, vials and syringes, one of few qualified suppliers to a concentrated glass-tubing market.
- Bear
- Pharma tubing is a minor line within a conglomerate dominated by display, glass fiber and electronics, leaving a speculative OTC name with negligible direct exposure.
SCHOTT Pharma AG & Co. KGaA (ADR)
Drug-containment and delivery pure play; FY2025 revenue ~€986M, high-value solutions 57% of Q1 FY2026 sales. Inaugurated >\$60M largely BARDA-funded vial expansion in Lebanon, PA (June 3, 2026) that more than triples US high-value capacity; FY2026 guidance 2-5% constant-currency growth.
- Bull
- SCHOTT Pharma is a drug-containment pure-play with high-value solutions at 57% of Q1 sales and a BARDA-funded Lebanon, PA expansion tripling US high-value vial capacity.
- Bear
- FY2026 guidance is just 2-5% constant-currency growth and access is via OTC ADR, tempering the pace of the high-value containment ramp.
Stevanato Group S.p.A.
Stevanato makes prefilled syringes (Nexa, its fastest-growing product), EZ-fill vials and cartridges for biologics and GLP-1 drugs. FY2025 revenue was EUR 1.186B (+7%, +9% constant currency), with GLP-1s ~19-20% of sales and GLP-1 revenue up >50% y/y; its Fishers, Indiana plant is being built as the North American high-value hub, reaching full productivity in 2028.
- Bull
- Stevanato's Nexa syringes, EZ-fill vials and cartridges sit across three chokepoints, with FY2025 revenue up 7% and GLP-1 revenue up >50% as its Fishers hub builds out.
- Bear
- The Fishers North American hub only reaches full productivity in 2028, so near-term margins absorb ramp costs ahead of the high-value capacity coming online.
Catalyst calendar
- 2026-12-18BIOSECURE Act OMB 'companies of concern' initial list deadline (one year from enactment)highFrames the US-onshoring tailwind backing BARDA-funded domestic vial capacity, even though the Act targets Chinese biotech CDMO services rather than glass packaging directly.
- 2026-07-28Corning Q2 2026 earningsmediumLife Sciences segment commentary and any Velocity vial/pharma tubing color sizes Corning's exposure to the glass chokepoint, though the print is dominated by optical/AI-glass.
- 2026-08-04Stevanato Group Q2 2026 earningsmediumTests the high-value-solutions mix ramp and GLP-1 demand, plus progress on the BARDA-funded Fishers, IN vial lines turning gross-margin positive.
- 2026-08-12SCHOTT Pharma Q3 FY2026 quarterly statementmediumReads through on high-value/RTU vial and syringe demand and the ramp of the newly inaugurated Lebanon, PA capacity against the 2-5% FY2026 growth guide.